The PROSASH and PROSASH-II model, which consisted of serum albumin, bilirubin, AFP, macrovascular invasion, extrahepatic spread, and largest tumor size, could predict the survival of patients with HCC treated with sorafenib (26, 27). Here, AFP is linked to neoplasm.